Advances in Molecular and Clinical Subtyping of Breast Cancer and Their Implications for Therapy

Surgical Oncology Clinics of North America

Volumn 22, Issue 4, 2013, Pages 823-840

  Cadoo, Karen A ^a   Traina, Tiffany A ^a   King, Tari A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Breast cancer; Endocrine therapy; HER2 positive; Intrinsic subtypes; Resistance; Triple negative

Indexed keywords

ANASTROZOLE; ANDROGEN RECEPTOR; AROMATASE INHIBITOR; BICALUTAMIDE; BUPARLISIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CLAUDIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EVEROLIMUS; EXEMESTANE; FULVESTRANT; IRINOTECAN; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PICTILISIB; PLATINUM COMPLEX; PROTEIN PIK3CA; RAPAMYCIN; TAMOXIFEN; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG;

ANEMIA; BASAL LIKE BREAST CANCER; BREAST CANCER; BREAST METASTASIS; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; DRUG RESPONSE; DYSPNEA; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HER2 GENE; HUMAN; HYPERGLYCEMIA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PNEUMONIA; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STOMATITIS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER;

BREAST CANCER; ENDOCRINE THERAPY; HER2 POSITIVE; INTRINSIC SUBTYPES; RESISTANCE; TRIPLE NEGATIVE;

ANIMALS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; PROGNOSIS;

EID: 84883552212     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2013.06.006     Document Type: Review

References (95)

1. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100(14):8418-8423.
2. Sotiriou C., Pusztai L. Gene-expression signatures in breast cancer. NEngl J Med 2009, 360(8):790-800.
3. Sotiriou C., Piccart M.J. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?. Nat Rev Cancer 2007, 7(7):545-553.
4. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752.
5. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98(19):10869-10874.
6. Herschkowitz J.I., Simin K., Weigman V.J., et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007, 8(5):R76.
7. Hu Z., Fan C., Oh D.S., et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96.
8. O'Brien K.M., Cole S.R., Tse C.K., et al. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 2010, 16(24):6100-6110.
9. Prat A., Parker J.S., Karginova O., et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010, 12(5):R68.
10. Carey L.A., Dees E.C., Sawyer L., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13(8):2329-2334.
11. Rouzier R., Perou C.M., Symmans W.F., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11(16):5678-5685.
12. Eroles P., Bosch A., Perez-Fidalgo J.A., et al. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev 2012, 38(6):698-707.
13. Kennecke H., Yerushalmi R., Woods R., et al. Metastatic behavior of breast cancer subtypes. JClin Oncol 2010, 28(20):3271-3277.
14. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490(7418):61-70.
15. Gnant M., Harbeck N., Thomssen C. St. Gallen 2011: Summary of the consensus discussion. Breast Care (Basel) 2011, 6(2):136-141.
16. Creighton C.J. The molecular profile of luminal B breast cancer. Biologics 2012, 6:289-297.
17. Colozza M., de Azambuja E., Cardoso F., et al. Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. Oncologist 2006, 11(2):111-125.
18. Parker J.S., Mullins M., Cheang M.C., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. JClin Oncol 2009, 27(8):1160-1167.
19. Perou C.M. Molecular stratification of triple-negative breast cancers. Oncologist 2011, 16(Suppl 1):61-70.
20. Carey L.A., Perou C.M., Livasy C.A., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295(21):2492-2502.
21. Rakha E.A., Reis-Filho J.S., Ellis I.O. Basal-like breast cancer: a critical review. JClin Oncol 2008, 26(15):2568-2581.
22. Rakha E.A., El-Rehim D.A., Paish C., et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 2006, 42(18):3149-3156.
23. Nielsen T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10(16):5367-5374.
24. Prat A., Perou C.M. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011, 5(1):5-23.
25. Gokmen-Polar Y., Badve S. Molecular profiling assays in breast cancer: are we ready for prime time?. Oncology (Williston Park) 2012, 26(4):350-357. 61.
26. Guiu S., Michiels S., Andre F., et al. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol 2012, 23(12):2997-3006.
27. Colombo P.E., Milanezi F., Weigelt B., et al. Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction. Breast Cancer Res 2011, 13(3):212.
28. van de Vijver M.J., He Y.D., van't Veer L.J., et al. Agene-expression signature as apredictor of survival in breast cancer. NEngl J Med 2002, 347(25):1999-2009.
29. Buyse M., Loi S., van't Veer L., et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. JNatl Cancer Inst 2006, 98(17):1183-1192.
30. Mook S., Schmidt M.K., Weigelt B., et al. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol 2010, 21(4):717-722.
31. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. JClin Oncol 2006, 24(23):3726-3734.
32. Paik S., Shak S., Tang G., et al. Amultigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. NEngl J Med 2004, 351(27):2817-2826.
33. Albain K.S., Barlow W.E., Shak S., et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010, 11(1):55-65.
34. Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896, 2:104-107.
35. Sainsbury R. The development of endocrine therapy for women with breast cancer. Cancer Treat Rev 2013, 39(5):507-517.
36. Chang J., Fan W. Endocrine therapy resistance: current status, possible mechanisms and overcoming strategies. Anticancer Agents Med Chem 2013, 13(3):464-475.
37. Klijn J.G., Beex L.V., Mauriac L., et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. JNatl Cancer Inst 2000, 92(11):903-911.
38. Baselga J., Campone M., Piccart M., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. NEngl J Med 2012, 366(6):520-529.
39. Gnant M. Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition. Expert Rev Anticancer Ther 2012, 12(12):1579-1589.
40. Roop R.P., Ma C.X. Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies. Future Oncol 2012, 8(3):273-292.
41. Clark A.S., West K., Streicher S., et al. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002, 1(9):707-717.
42. deGraffenried L.A., Friedrichs W.E., Russell D.H., et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 2004, 10(23):8059-8067.
43. Ghayad S.E., Bieche I., Vendrell J.A., et al. mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci 2008, 99(10):1992-2003.
44. Bachelot T., Bourgier C., Cropet C., et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. JClin Oncol 2012, 30(22):2718-2724.
45. Bhattacharyya GS, Biswas J, Singh JK, etal. Reversal of tamoxifen resistance (hormone resistance) by addition of sirolimus (mTOR inhibitor) in metastatic breast cancer. European Multidisciplinary Cancer Conference, Stockholm. September 23-27, 2011. [abstract LBA16].
46. Wolff A.C., Lazar A.A., Bondarenko I., et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. JClin Oncol 2013, 31(2):195-202.
47. Dees E.C., Carey L.A. Improving endocrine therapy for breast cancer: it's not that simple. JClin Oncol 2013, 31(2):171-173.
48. Rugo H.S., Keck S. Reversing hormone resistance: have we found the golden key?. JClin Oncol 2012, 30(22):2707-2709.
49. Miller T.W., Balko J.M., Arteaga C.L. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. JClin Oncol 2011, 29(33):4452-4461.
50. Baselga J., Campone M., Cortes J., et al. Phase III randomized study of the oral pan-PI3K inhibitor BKM120 with fulvestrant in postmenopausal women with HR+/HER2- locally advanced or metastatic breast cancer resistant to aromatase inhibitor - BELLE-2. Cancer Res 2012, 72(Suppl 24). [abstract OT2-3-09].
51. Fox E.M., Arteaga C.L., Miller T.W. Abrogating endocrine resistance by targeting ERalpha and PI3K in breast cancer. Front Oncol 2012, 2:145.
52. Cortes J., Baselga J. How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer. JClin Oncol 2009, 27(33):5492-5494.
53. Leary A.F., Drury S., Detre S., et al. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin Cancer Res 2010, 16(5):1486-1497.
54. Kaufman B., Mackey J.R., Clemens M.R., et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. JClin Oncol 2009, 27(33):5529-5537.
55. Johnston S., Pippen J., Pivot X., et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. JClin Oncol 2009, 27(33):5538-5546.
56. Cristofanilli M., Valero V., Mangalik A., et al. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res 2010, 16(6):1904-1914.
57. Gutteridge E., Agrawal A., Nicholson R., et al. The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study. Int J Cancer 2010, 126(8):1806-1816.
58. Osborne C.K., Neven P., Dirix L.Y., et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res 2011, 17(5):1147-1159.
59. Study of Anastrozole+/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer (MINT). ClinicalTrials.gov Identifier: NCT01151215. Available at: Accessed March 10, 2013. http://clinicaltrials.gov/ct2/show/NCT01151215.
60. Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice. NEngl J Med 2007, 357(1):39-51.
61. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235(4785):177-182.
62. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244(4905):707-712.
63. Junttila T.T., Akita R.W., Parsons K., et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009, 15(5):429-440.
64. Cuello M., Ettenberg S.A., Clark A.S., et al. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 2001, 61(12):4892-4900.
65. Yakes F.M., Chinratanalab W., Ritter C.A., et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002, 62(14):4132-4141.
66. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. NEngl J Med 2001, 344(11):783-792.
67. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. NEngl J Med 2005, 353(16):1659-1672.
68. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. NEngl J Med 2005, 353(16):1673-1684.
69. Gianni L., Eiermann W., Semiglazov V., et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010, 375(9712):377-384.
70. Untch M., Rezai M., Loibl S., et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. JClin Oncol 2010, 28(12):2024-2031.
71. Esteva F.J., Guo H., Zhang S., et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 2010, 177(4):1647-1656.
72. Berns K., Horlings H.M., Hennessy B.T., et al. Afunctional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12(4):395-402.
73. Nagata Y., Lan K.H., Zhou X., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6(2):117-127.
74. Mittendorf E.A., Wu Y., Scaltriti M., et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 2009, 15(23):7381-7388.
75. Scaltriti M., Rojo F., Ocana A., et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. JNatl Cancer Inst 2007, 99(8):628-638.
76. Chandarlapaty S., Sakr R.A., Giri D., et al. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin Cancer Res 2012, 18(24):6784-6791.
77. Blackwell K.L., Burstein H.J., Storniolo A.M., et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. JClin Oncol 2010, 28(7):1124-1130.
78. Baselga J., Bradbury I., Eidtmann H., et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012, 379(9816):633-640.
79. ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D. ClinicalTrials.gov Identifier: NCT00490139. Available at: Accessed March 27, 2013. http://clinicaltrials.gov/ct2/show/NCT00490139.
80. Baselga J., Gelmon K.A., Verma S., et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. JClin Oncol 2010, 28(7):1138-1144.
81. Baselga J., Cortes J., Kim S.B., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. NEngl J Med 2012, 366(2):109-119.
82. Gianni L., Pienkowski T., Im Y.H., et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13(1):25-32.
83. Thompson C.A. CMS tackles patients' use of home medications at hospitals, MTM program fulfillment. Am J Health Syst Pharm 2013, 70(7):562-565.
84. Dent R., Trudeau M., Pritchard K.I., et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007, 13(15):4429-4434.
85. Lehmann B.D., Bauer J.A., Chen X., et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. JClin Invest 2011, 121(7):2750-2767.
86. Byrski T., Gronwald J., Huzarski T., et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. JClin Oncol 2010, 28(3):375-379.
87. Silver D.P., Richardson A.L., Eklund A.C., et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. JClin Oncol 2010, 28(7):1145-1153.
88. Isakoff S.J., Goss P.E., Mayer E.L., et al. TBCRC009: A multicenter phase II study ofcisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. JClin Oncol 2011, 29(15, Suppl). [abstract 1025].
89. Carey L.A., Rugo H.S., Marcom P.K., et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. JClin Oncol 2012, 30(21):2615-2623.
90. O'Shaughnessy J., Weckstein D., Vukelja S. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 2007, 106:S32. [abstract 308, presented data at SABCS 2007].
91. Baselga J., Stemmer S., Pego A. Cetuximab+ cisplatin in estrogen receptor-negative, progesterone receptor-negative, HER2-negative (triple-negative) metastatic breast cancer: results of the randomized phase II BALI-1 trial. Cancer Res 2010, 70(24, Suppl 2). PD01-01. Presented data at SABCS 2010.
92. Doane A.S., Danso M., Lal P., et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006, 25(28):3994-4008.
93. Farmer P., Bonnefoi H., Becette V., et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005, 24(29):4660-4671.
94. Gucalp A., Tolaney S., Isakoff S. Targeting the androgen receptor (AR) in women with AR+ ER-/PR- metastatic breast cancer (MBC). JClin Oncol 2012, 30(Suppl). [abstract 1006].
95. Ng CH, Macpherson I, Rea D, etal. Phase I/II trial of abiraterone acetate (AA) in estrogen receptor (ERα) or androgen receptor (AR) positive metastatic breast cancer (MBC). Presented at the ESMO 2012 Conference, Vienna, September 28-October 2, 2012.